{"filings":[{"id":92603,"accession_number":"0001193125-26-197124","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q1 revenue up 224% to $64.9M; net loss narrows to $42.7M from $84.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revuforj net revenue $48.9M (+144% YoY, +11% QoQ); total prescriptions up ~160% YoY.","Niktimvo net revenue $55.1M; Syndax collaboration revenue $15.9M (50% of profit share).","Net loss $0.48/share vs $0.98/share prior year; cash and investments $352.1M.","FY2026 opex guidance ~$400M (excl. $50M stock comp); expects to reach profitability.","Topline data from Phase 2 axatilimab trials in IPF and frontline chronic GVHD expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":64864000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103552,"accession_number":"0001193125-26-076522","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q4 Revuforj $44.2M (+38% QoQ); Niktimvo $56M; net loss $68M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $68.7M in Q4 and $172.4M in FY2025, driven by Revuforj and Niktimvo launches.","Revuforj net revenue $44.2M in Q4 (+38% vs Q3) and $124.8M in FY2025; ~1,150 prescriptions in Q4.","Niktimvo net revenue $56M in Q4 (+22% vs Q3) and $151.6M in FY2025; Syndax collaboration revenue $42.4M FY.","Net loss $68M (0.78/share) in Q4 and $285.4M ($3.29/share) for FY2025; cash $394.1M at year-end.","FY2026 opex guidance ~$400M ex-stock comp; expects profitability from cash, revenue, and interest income."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":172352000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103551,"accession_number":"0001193125-26-010486","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Syndax reports preliminary 2025 Revuforj $125M, Niktimvo $152M net rev, cash $394M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revuforj preliminary net revenue $44M (Q4) and $125M (FY), up 38% QoQ.","Niktimvo preliminary net revenue $56M (Q4) and $152M (FY); Syndax's 50% profit share expected ~25-30% of net rev.","Cash, equivalents and marketable securities ~$394M at year-end 2025 (unaudited).","2026 R&D + SG&A expense guidance ~$400M (excl. $50M non-cash stock comp); company funded to profitability.","Key 2026 milestones: complete IPF trial enrollment, advance frontline Phase 3 revumenib trials, initiate MF proof-of-principle."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":172352000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119816,"accession_number":"0001193125-25-326961","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Syndax amends Bylaws to move to uncertificated shares effective Dec 18, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Bylaw amendment on Dec 18, 2025 requiring all future share issuances to be uncertificated.","Existing physical certificates issued prior to Dec 18, 2025 remain valid until surrendered.","Amendment is administrative; no change to shareholder rights or capital structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119815,"accession_number":"0001193125-25-262509","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax reports Q3 2025 revenue $45.9M, Revuforj net sales $32M; FDA approval for NPM1m AML on Oct 24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $45.9M (Revuforj net $32.0M, +12% vs Q2; Niktimvo collab $13.9M).","Net loss $60.7M ($0.70/sh) vs $84.1M ($0.98/sh) year-ago; cash $456.1M.","Revuforj FDA-approved for R/R NPM1m AML Oct 24, 2025; added to NCCN Guidelines as cat 2A.","Full-year 2025 R&D+SG&A guidance narrowed to $380-$385M; expects to reach profitability.","Total Revuforj prescriptions ~850 in Q3 (+25% vs Q2); Niktimvo net sales reported by Incyte $45.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":103624000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119814,"accession_number":"0001193125-25-250052","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax receives FDA approval for Revuforj in NPM1-mutated R/R AML, second indication in <1 year","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Revuforj (revumenib) for R/R AML with NPM1 mutation in patients aged ≥1 year.","CR+CRh rate of 23% (15/65); median time to response 2.8 months; median duration 4.5 months.","First and only FDA-approved menin inhibitor for both NPM1-m AML and KMT2A-r acute leukemia.","Included in NCCN Guidelines (Category 2A) for R/R NPM1m AML; commercial launch ongoing via SyndAccess.","Company to host conference call on Oct 24, 2025 at 2:30 p.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136369,"accession_number":"0000950170-25-101974","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q2 Revuforj revenue $28.6M (+43% QoQ); sNDA for mNPM1 AML with Priority Review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revuforj net revenue $28.6M in Q2 2025, 43% increase over Q1 2025.","Niktimvo net revenue $36.2M (Incyte-reported); Syndax collaboration revenue $9.4M.","sNDA for Revuforj in R/R mNPM1 AML granted Priority Review; PDUFA Oct 25, 2025.","Cash, cash equivalents and investments $517.9M; expect funding to profitability.","Net loss $71.8M ($0.83/sh) vs $68.1M ($0.80/sh) year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":57753000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153510,"accession_number":"0000950170-25-090205","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director William Meury resigns from Syndax board to become Incyte CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Meury resigned from Syndax board effective June 24, 2025.","Meury accepted roles of President, CEO, and board member at Incyte Corporation.","Incyte is Syndax's collaboration partner for Niktimvo (axatilimab-csfr).","Resignation not due to any disagreement with Syndax's operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153509,"accession_number":"0000950170-25-073555","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Syndax names Dr. Nicholas Botwood Head of R&D and CMO, replacing Neil Gallagher","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Nicholas Botwood appointed Head of R&D and CMO, effective May 12, 2025; succeeds Dr. Neil Gallagher who is departing.","Botwood most recently SVP, Head of Worldwide Medical Oncology at BMS; brings 25+ years oncology development experience.","Employment terms: base salary $540K, annual target bonus 45%, stock option for 215K shares, PRSU of 23,400 units.","Gallagher will remain for interim transition period; thanked for contributions including two product approvals.","Annual meeting results: all director nominees elected, say-on-pay approved (62.5M for), auditor ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153508,"accession_number":"0000950170-25-063514","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Syndax Q1 Revuforj rev $20M, Niktimvo rev $13.6M; sNDA for mNPM1 AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revuforj net revenue $20.0M in first full quarter; Niktimvo net revenue $13.6M (Incyte reported) in first partial quarter.","Submitted sNDA seeking Priority Review for revumenib in R/R mNPM1 AML under FDA RTOR program.","Initiated EVOLVE-2 pivotal frontline trial of revumenib + venetoclax/azacitidine in mNPM1 and KMT2Ar AML.","Net loss $84.8M ($0.98 per share) vs $72.4M ($0.85 per share) year ago; cash $602.1M.","Full-year 2025 R&D guidance $260-280M, total R&D+SG&A $415-435M; expects to reach profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":20042000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172244,"accession_number":"0000950170-25-030392","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Syndax Q4 Revuforj revenue $7.7M; net loss $94.2M; cash $692.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 Revuforj net product revenue $7.7M in first five weeks of U.S. launch.","Net loss $94.2M ($1.10/share) for Q4 2024 vs $72.5M ($1.00) in Q4 2023; full year net loss $318.8M ($3.72).","Cash, equivalents and investments $692.4M; expects current resources to fund to profitability.","Launched Niktimvo in Jan 2025 with Incyte; $350M royalty funding from Royalty Pharma on Niktimvo sales.","sNDA for revumenib in R/R mNPM1 AML expected Q2 2025 based on positive AUGMENT-101 data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189234,"accession_number":"0000950170-24-139121","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Syndax eliminates Chief Medical Officer role; Dr. Catherine Madigan departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Catherine Madigan, M.D. ceased employment effective December 20, 2024, after position eliminated.","Severance compensation consistent with service agreement terms (Exhibits 10.24, 10.25 to 2023 10-K).","No replacement appointed; company restructures clinical leadership without a CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189233,"accession_number":"0000950170-24-127708","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax receives FDA approval for Revuforj as first menin inhibitor for KMT2A-translocated acute leukemia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Revuforj for R/R acute leukemia with KMT2A translocation in patients aged 1+ years.","Efficacy: CR+CRh rate 21% (22/104), median duration 6.4 months, median time to remission 1.9 months.","Safety: common AEs include hemorrhage, febrile neutropenia, differentiation syndrome; 12% discontinued.","Commercial launch of 110/160 mg tablets expected Nov 2024; 25 mg tablets in early 2025.","SyndAccess patient support program launched; oral solution available via expanded access for patients <40 kg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189232,"accession_number":"0000950170-24-124545","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax reports positive pivotal Phase 2 results for revumenib in R/R mNPM1 AML; CR/CRh 23%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: CR/CRh rate 23% (15/64; 95% CI 14%–36%; p=0.0014) in efficacy-evaluable adult patients.","ORR 47% (30/64); 75% had prior venetoclax; 36% received ≥3 prior lines of therapy.","Safety profile consistent; 5% discontinued due to TRAEs. Grade ≥3 TRAEs: QTc prolongation 21%, anemia 14%, febrile neutropenia 13%, DS 13%, platelet count decreased 11%.","sNDA filing for R/R mNPM1 AML expected in 1H25; FDA decision on KMT2Ar acute leukemias expected in 4Q24."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189231,"accession_number":"0000950170-24-121437","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q3 net loss $84.1M; revumenib PDUFA Dec 26; Niktimvo approved; $350M royalty funding","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $84.1M ($0.98/share) vs $51.1M ($0.73) in Q3 2023; R&D $71.0M, SG&A $31.1M.","Revumenib NDA under FDA RTOR with PDUFA Dec 26, 2024; topline mNPM1 AML data expected Q4 2024, potential sNDA 1H25.","Niktimvo (axatilimab) approved by FDA for chronic GVHD after ≥2 prior lines; launch early Q1 2025.","$350M royalty funding agreement with Royalty Pharma (13.8% royalty on U.S. Niktimvo sales) expected to fund to profitability.","Full-year 2024 guidance: R&D $245-250M, total op. exp. $365-370M; cash $399.6M as of Sep 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":16000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189230,"accession_number":"0000950170-24-120673","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Syndax sells 13.8% royalty on Niktimvo (axatilimab) to Royalty Pharma for $350M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Pharma acquires right to 13.8% of net sales of Niktimvo (axatilimab) in US and territories.","Upfront payment of $350M; aggregate payments to Royalty Pharma capped at $822.5M.","Royalty rate subject to adjustments based on future aggregate net sales.","Syndax retains repurchase right upon change of control; events of default trigger mandatory repurchase at cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205727,"accession_number":"0000950170-24-089235","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q2 net loss $68.1M, revumenib PDUFA extended to Dec 26, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $68.1M ($0.80/sh) vs $44.6M ($0.64/sh) in Q2 2023; cash $454.6M as of June 30.","R&D expenses $48.7M, SG&A $29.1M; FY2024 opex guidance $355-375M with sufficient capital through 2026.","Revumenib NDA for R/R KMT2Ar leukemia PDUFA extended to Dec 26, 2024; AUGMENT-101 mNPM1 AML data expected 4Q24.","Axatilimab BLA for chronic GVHD under Priority Review with PDUFA date Aug 28, 2024.","Appointed Dr. Aleksandra Rizo to Board of Directors in May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":3500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222668,"accession_number":"0000950170-24-060462","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Syndax appoints Aleksandra Rizo to Board; Morrison resigns; annual meeting votes passed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aleksandra Rizo, M.D., Ph.D., elected to Board effective May 15, replacing Briggs Morrison who resigned.","Dr. Rizo receives $45,644 annual cash for Board service, $8,558 for Science & Technology Committee, plus initial option for 35,000 shares vesting monthly over three years.","Annual meeting results: all director nominees elected (Huber 61.9M for, Jarrett 39.5M for), executive compensation advisory vote passed (46.2M for, 16.3M against), auditor ratified (65.4M for).","Dr. Rizo is President/CEO of Vividion, brings hematology clinical development and regulatory experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222667,"accession_number":"0000950170-24-055052","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q1 net loss $72.4M ($0.85/shr); revumenib NDA & axatilimab BLA under Priority Review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $522M; management believes sufficient for operations through 2026.","Revumenib NDA for R/R KMT2Ar acute leukemia granted Priority Review; PDUFA date Sep 26, 2024.","Axatilimab BLA for chronic GVHD granted Priority Review; PDUFA date Aug 28, 2024.","Enrollment completed in AUGMENT-101 mNPM1 cohort; topline data expected 4Q24, potential sNDA 1H25.","Appointed Steven Closter as Chief Commercial Officer; R&D expenses rose to $56.5M from $34.1M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}